市場調查報告書

全球自體細胞治療藥市場:成長,趨勢,及預測(2020年∼2025年)

Autologous Cell Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921873
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球自體細胞治療藥市場:成長,趨勢,及預測(2020年∼2025年) Autologous Cell Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 112 Pages
簡介

全球自體細胞治療藥市場在預測期間內預計將以15.9%的年複合成長率增長。推動了該市場成長的主要因素是慢性疾病(例如自體免疫疾病,癌症,血液疾病等慢性疾病)的發病率上升,以及患有慢性疾病的人口不斷增長。在將自體細胞治療市場推向新高度的過程中,發揮重要作用的一個因素是正在進行的新用途藥物開發,有望進一步推動市場的增長。

本報告提供全球自體細胞治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各療法·用途·材料·終端用戶·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 慢性疾病的發生率的上升
    • 進一步專注於新應用的藥物開發
  • 市場阻礙因素
    • 全身性免疫反應的可能性
    • 高昂的實施成本,產品和高資本投資
  • 波特的五力分析

第5章 市場區隔

  • 各療法
    • 自體幹細胞療法
    • 自我細胞免疫療法
  • 各用途
    • 腫瘤學
    • 肌肉骨骼障礙
    • 血液疾病
    • 自體免疫疾病
    • 其他
  • 不同材料
    • 骨髓
    • 表皮
    • 其他
  • 各終端用戶
    • 醫院
    • 研究中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Vericel Corporation
    • Pharmicell Co., Inc.
    • Holostem Terapie Avanzate Srl
    • Lineage Cell Therapeutics, Inc.
    • Opexa Therapeutics
    • BrainStorm Cell Therapeutics
    • Sangamo Therapeutics

第7章 市場機會及今後趨勢

目錄
Product Code: 67508

The Autologous Cell Therapy market studied was anticipated to grow with a CAGR of 15.9%, during the forecast period. The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, blood disorder, and others. A rise in the population suffering from chronic diseases is also propelling the demand for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future. As per the CDC (Centers for Disease Control and Prevention) estimates Sickel Cell Disease (SCD) affects around 100,000 Americans annually. And there are few more factors which are playing crucial roles in taking the autologous cell therapy market to the next level, among them one is on-going drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market.

Key Market Trends

Bone Marrow Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market

  • Bone marrow transplant is a technique for replacing damaged and destroyed cells with new stem cells in the bone marrow.
  • Bone marrow is the most commonly used for autologous cell therapy as it can benefit individuals with a range of cancer (malignant) and non-cancer (benign) diseases and will drive the market during the forecast period.
  • As per the statistics from Globocan 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, blood disorder, autoimmune diseases, and other diseases and the availability of advanced healthcare infrastructure among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer and other chronic diseases, along with the rising geriatric population and developments related to stem cell therapy and rising demand for biotechnological practices in the country, is anticipated to further drive the demand in this region.

Competitive Landscape

The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., and Opexa Therapeutics.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Chronic Diseases
    • 4.2.2 Emphasis Increasingly on Drug Development for New Applications
  • 4.3 Market Restraints
    • 4.3.1 Systemic immunological reactions possibility
    • 4.3.2 Expensive practise, product and high capital investment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Autologous Stem Cell Therapy
    • 5.1.2 Autologous Cellular Immunotherapies
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Musculoskeletal Disorder
    • 5.2.3 Blood Disorder
    • 5.2.4 Autoimmune Disease
    • 5.2.5 Others
  • 5.3 By Source
    • 5.3.1 Bone Marrow
    • 5.3.2 Epidermis
    • 5.3.3 Others
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Research Centers
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 The United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Vericel Corporation
    • 6.1.2 Pharmicell Co., Inc.
    • 6.1.3 Holostem Terapie Avanzate S.r.l.
    • 6.1.4 Lineage Cell Therapeutics, Inc.
    • 6.1.5 Opexa Therapeutics
    • 6.1.6 BrainStorm Cell Therapeutics
    • 6.1.7 Sangamo Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS